Active substances set

Search phrase: non-Hodgkin lymphoma

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

non-Hodgkin lymphoma

Obinutuzumab	Obinutuzumab in combination with chemotherapy, followed by Obinutuzumab maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced FL. Obinutuzumab in combination with bendamustine followed by Obinutuzumab maintenance is indicated for the treatment of patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.	NO REIMBURSEMENT ESMO
Loncastuximab tesirine	Loncastuximab tesirine as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.	NO REIMBURSEMENT ESMO
Zanubrutinib	Zanubrutinib in combination with obinutuzumab is indicated for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.	NO REIMBURSEMENT ESMO
Odronextamab	Odronextamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy.	NO REIMBURSEMENT ESMO

Ibrutinib	Ibrutinib as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).	REIMBURSEMENT WITH RESTRICTIONS ESMO
Lenalidomide	Lenalidomide in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). Lenalidomide as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.	REIMBURSEMENT WITH RESTRICTIONS ESMO
Axicabtagene ciloleucel	Axicabtagene ciloleucel is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. Axicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Axicabtagene ciloleucel is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy.	REIMBURSEMENT WITH RESTRICTIONS ESMO
Tisagenlecleucel	Tisagenlecleucel is indicated for the treatment of: - Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. - Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.	REIMBURSEMENT WITH RESTRICTIONS ESMO
Polatuzumab vedotin	Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Polatuzumab vedotin in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.	REIMBURSEMENT WITH RESTRICTIONS ESMO
Brexucabtagene autoleucel	Mantle cell lymphoma Brexucabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.	REIMBURSEMENT WITH RESTRICTIONS ESMO

Tafasitamab	Tafasitamab is indicated in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).	REIMBURSEMENT WITH RESTRICTIONS ESMO
Lisocabtagene maraleucel	Lisocabtagene maraleucel is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. Lisocabtagene maraleucel is indicated for the treatment of adult patients with relapsed or refractory DLBCL, PMBCL and FL3B, after two or more lines of systemic therapy.	REIMBURSEMENT WITH RESTRICTIONS ESMO
Epcoritamab	Epcoritamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Epcoritamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.	REIMBURSEMENT WITH RESTRICTIONS ESMO
Pirtobrutinib	Pirtobrutinib as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.	REIMBURSEMENT WITH RESTRICTIONS ESMO
Acalabrutinib	Aacalabrutinib in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant (ASCT). Aacalabrutinib as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) not previously treated with a BTK inhibitor.	REIMBURSEMENT WITH RESTRICTIONS ESMO
Mosunetuzumab	Mosunetuzumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.	FULL REIMBURSEMENT ESMO
Glofitamab	Glofitamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.	FULL REIMBURSEMENT ESMO